What Is Neuromedin U? Definition and What Research Reports

Definition

Neuromedin U (NMU) is a neuropeptide — a short chain of amino acids released by nerve cells and certain endocrine cells that acts as a signalling molecule rather than as a structural protein. It was originally identified from gut tissue and named for its ability to contract uterine smooth muscle, and it has since been described across a wide range of vertebrates. NMU circulates in several length variants depending on species (commonly referred to by residue count, such as the 25-residue human form and the 23-residue rat form), all sharing a conserved, amidated C-terminal region that is required for receptor binding. It signals through two G protein-coupled receptors, NMUR1 and NMUR2, which are distributed differently: NMUR1 is associated more with peripheral tissues, including immune cells, and NMUR2 more with the central nervous system. In peptide research, "neuromedin U" refers to the endogenous peptide and its synthetic analogues used as laboratory tools, not to any approved therapeutic product.

Where It Comes From

NMU is encoded by the NMU gene and produced as a larger precursor protein that is cleaved and amidated to yield the active peptide. The highest expression in most species has been mapped to the gastrointestinal tract and to discrete regions of the brain and spinal cord, with additional expression reported in other peripheral tissues. Comparative work has extended this mapping beyond the standard rodent models: a 2017 study cloned neuromedin U and its receptors in pigs and described their expression patterns across porcine tissues (PMID 28434792), illustrating how conserved the peptide–receptor system is across mammals.

Because NMU is made by neurons that sit close to epithelial and immune cells — particularly in the intestine and airway — much of the contemporary literature treats it as a neuro-immune messenger: a molecule through which the nervous system communicates directly with immune cells.

How the Term Is Used in Peptide Research

In published research, "neuromedin U" appears in several distinct contexts:

• As a receptor ligand. Studies apply NMU peptide to cells or tissues expressing NMUR1 or NMUR2 to characterise downstream signalling.
• As a biomarker. Observational work measures circulating NMU concentrations in people with particular conditions and compares them with controls.
• As a genetic target. Knockout animals lacking NMU or its receptors are used to test what the peptide contributes to a physiological process.
• As a neuro-immune signal. Co-culture and in vivo models examine how neuron-derived NMU acts on immune cell populations.

What the Published Literature Reports

Neuro-immune signalling and type 2 immunity

The most heavily cited line of NMU research concerns group 2 innate lymphoid cells (ILC2s). Two 2017 Nature papers published in parallel reported that the neuropeptide neuromedin U stimulated innate lymphoid cells and drove type 2 inflammation (PMID 28869965), and that neurons regulated type 2 innate lymphoid cells via neuromedin U acting through the NMUR1 receptor expressed on those cells (PMID 28869974). Researchers described this as evidence of a direct neuronal-to-immune circuit at mucosal surfaces.

Later work extended the finding to human cells and tissues. A 2022 study in Mucosal Immunology reported that neuromedin U promoted human type 2 immune responses (PMID 35810259). A 2024 paper in the American Journal of Respiratory and Critical Care Medicine reported that neuromedin U mediated rapid activation of airway group 2 innate lymphoid cells in people with mild asthma (PMID 38598774). A 2023 Science paper widened the cellular scope beyond ILC2s, reporting that neuromedin U programmed eosinophils to promote mucosal immunity of the small intestine (PMID 37708282).

Metabolism and body weight

NMU was long discussed as an anorexigenic peptide, but genetic and pharmacological work in rats has complicated that picture. A 2022 Scientific Reports study reported that neuromedin U-deficient rats did not lose body weight or reduce food intake as the earlier mouse literature had suggested (PMID 36302800). Separately, a 2019 Cell Metabolism paper reported that neuromedin U did not act as a decretin — that is, as a gut-derived suppressor of insulin secretion — in rats (PMID 30449683). Both are examples of the literature revising an earlier hypothesis rather than confirming it, and readers comparing sources should note the species differences involved.

NMU as a measured biomarker

Several clinical observational studies have measured NMU concentrations rather than administering the peptide. A 2024 Heliyon analysis examined the association of neuromedin U levels with non-alcoholic fatty liver disease in a comparative design (PMID 38486771). A 2024 paper in ESC Heart Failure reported that the peptide neuromedin U was elevated in NYHA class II and III heart failure (PMID 38581170). Association studies of this kind describe a statistical relationship; they do not establish that the peptide caused the condition.

Other reported contexts

A 2020 study in Biochemical and Biophysical Research Communications reported that neuromedin U regulated osteoblast differentiation and activity (PMID 32057362), placing the peptide in bone biology as well. In oncology, a 2021 PeerJ paper reported that neuromedin U and neurotensin may promote the development of the tumour microenvironment in neuroblastoma (PMID 34141479). These are early-stage mechanistic findings in specific model systems.

Quick Reference Table

Safety and Adverse Events: What Studies Report

The verified literature summarised on this page consists of mechanistic laboratory work, animal genetic studies and observational human measurements; it does not include controlled human safety trials of administered neuromedin U, and none of the cited papers reported a tolerability or adverse-event profile for the peptide given to people. Where human data appear, they involved measuring endogenous NMU concentrations — as in the heart failure analysis that reported elevated NMU in NYHA II and III patients (PMID 38581170) — or characterising airway immune cell responses in mild asthma (PMID 38598774). Because the ILC2 findings link NMU to type 2 inflammation (PMID 28869965), researchers have generally framed the peptide as a pathway of interest rather than as a candidate with an established human safety record.

Limitations of the Current Evidence

1. Species differences are substantial. Findings in mice were not always reproduced in rats, as the body weight and decretin studies illustrate (PMID 36302800, PMID 30449683).
2. Association is not causation. Biomarker studies in liver disease reported a statistical association only (PMID 38486771).
3. Most work is mechanistic. The immunology literature describes cellular pathways rather than clinical outcomes (PMID 37708282).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or before making any decision related to a medication, supplement or investigational compound.

References

• Neuromedin U programs eosinophils to promote mucosal immunity of the small intestine (Science, 2023)
• The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation (Nature, 2017)
• Neuronal regulation of type 2 innate lymphoid cells via neuromedin U (Nature, 2017)
• Neuromedin-U Mediates Rapid Activation of Airway Group 2 Innate Lymphoid Cells in Mild Asthma (American Journal of Respiratory and Critical Care Medicine, 2024)
• Neuromedin U promotes human type 2 immune responses (Mucosal Immunology, 2022)
• Neuromedin U-deficient rats do not lose body weight or food intake (Scientific Reports, 2022)
• Neuromedin U Does Not Act as a Decretin in Rats (Cell Metabolism, 2019)
• The association of Neuromedin U levels and non-alcoholic fatty liver disease: A comparative analysis (Heliyon, 2024)
• The peptide neuromedin U (NMU) is elevated in NYHA II and III heart failure (ESC Heart Failure, 2024)
• Neuromedin U (NMU) regulates osteoblast differentiation and activity (Biochemical and Biophysical Research Communications, 2020)
• Neuromedin U and neurotensin may promote the development of the tumour microenvironment in neuroblastoma (PeerJ, 2021)
• Cloning and expression patterns of neuromedin U and its receptors in pigs (Neuropeptides, 2017)